IL28B single nucleotide polymorphisms in the treatment of hepatitis C - PubMed (original) (raw)
Review
. 2011 Sep;55(3):692-701.
doi: 10.1016/j.jhep.2011.03.006. Epub 2011 Mar 25.
Affiliations
- PMID: 21440591
- DOI: 10.1016/j.jhep.2011.03.006
Free article
Review
IL28B single nucleotide polymorphisms in the treatment of hepatitis C
Christian M Lange et al. J Hepatol. 2011 Sep.
Free article
Abstract
Recent genome-wide association studies (GWAS) have identified genetic variations near the IL28B gene which are strongly associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. Protective IL28B variations are strongly associated with on-treatment viral kinetics and approximately 2-fold increased sustained virologic response (SVR) rates in HCV genotype 1 and 4 patients. In HCV genotype 1 patients, IL28B variations were shown to be the strongest pre-treatment predictor of virologic response. In the treatment of HCV genotype 2 and 3 infected patients, IL28B variations play only a minor role. Preliminary data indicate that IL28B variations are also associated with treatment outcome of regimens, including directly acting antiviral (DAA) agents, though their impact seems to be attenuated compared to standard treatment. Here, we review these important findings and discuss possible implications for clinical decision making in the treatment of HCV infection.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
- Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L, Di Biagio A, Sartini M, Rappazzo E, Nicolini LA, Cenderello G, Valle C, Azzola E, Grasso A, De Leo P, Boldrini A, Setti M, Prinapori R, Lorusso C, Bruzzone B, Icardi G; Ligurian HIV Network. Sticchi L, et al. New Microbiol. 2015 Oct;38(4):499-509. Epub 2015 Oct 20. New Microbiol. 2015. PMID: 26485009 - Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ; ATAHC Study Group. Grebely J, et al. Hepatology. 2010 Oct;52(4):1216-24. doi: 10.1002/hep.23850. Hepatology. 2010. PMID: 20803561 Free PMC article. - Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.
Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Jiménez-Sousa MA, et al. BMC Med. 2013 Jan 8;11:6. doi: 10.1186/1741-7015-11-6. BMC Med. 2013. PMID: 23298311 Free PMC article. - IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.
Berger CT, Kim AY. Berger CT, et al. Infect Dis Clin North Am. 2012 Dec;26(4):863-77. doi: 10.1016/j.idc.2012.08.010. Infect Dis Clin North Am. 2012. PMID: 23083820 Free PMC article. Review. - The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.
Bellanti F, Vendemiale G, Altomare E, Serviddio G. Bellanti F, et al. Clin Dev Immunol. 2012;2012:849373. doi: 10.1155/2012/849373. Epub 2012 Aug 27. Clin Dev Immunol. 2012. PMID: 22966241 Free PMC article. Review.
Cited by
- Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment.
Dash S, Aydin Y, Widmer KE, Nayak L. Dash S, et al. J Hepatocell Carcinoma. 2020 Apr 15;7:45-76. doi: 10.2147/JHC.S221187. eCollection 2020. J Hepatocell Carcinoma. 2020. PMID: 32346535 Free PMC article. Review. - Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.
Tsiara CG, Nikolopoulos GK, Dimou NL, Pantavou KG, Bagos PG, Mensah B, Talias M, Braliou GG, Paraskeva D, Bonovas S, Hatzakis A. Tsiara CG, et al. J Genet. 2018 Mar;97(1):235-251. J Genet. 2018. PMID: 29666343 - The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.
Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. Kjellin M, et al. Ups J Med Sci. 2018 Mar;123(1):50-56. doi: 10.1080/03009734.2018.1441928. Epub 2018 Mar 14. Ups J Med Sci. 2018. PMID: 29536805 Free PMC article. - Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.
Palenzuela Gardón D, Guillen IA, Fernández JR, Camacho H, Estevez ZC, Dueñas S, Alvares-Lajonchere L, Amador Y, Martinez-Donato G, Han J, Zhang Z, Zhang X, Gao Y, Campaña JR, Novoa LI. Palenzuela Gardón D, et al. J Biomol Tech. 2017 Jul;28(2):80-86. doi: 10.7171/jbt.17-2801-001. Epub 2016 Dec 16. J Biomol Tech. 2017. PMID: 28058039 Free PMC article. - Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1Patients Treated by Pegylated Interferon and Ribavirin.
Safarnezhad Tameshkel F, Karbalaie Niya MH, Sohrabi M, Panahi M, Zamani F, Imanzade F, Rakhshani N. Safarnezhad Tameshkel F, et al. Iran J Pathol. 2016 Summer;11(3):216-221. Iran J Pathol. 2016. PMID: 27799970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical